Mylan’s $465 million settlement with the U.S. Justice Department last year for overcharging Medicaid millions of dollars for the Epipen has prompted two U.S. senators to introduce a bill aimed at preventing another similar “fiasco.”

Senate finance committee ranking member Ron Wyden, D-Oregon, and senior member Chuck Grassley, R-Iowa, said the Right Rebate Act would give Medicaid more authority and tools to go after drug makers suspected of misclassifying brand name drugs as generics.

Makers of generic drugs pay lower rebates to Medicaid, resulting in states and the federal government paying more for the product.

The act would give the U.S. Department of Health and Human Services more tools to monitor drug manufacturers who participate in the Medicaid Drug Rebate Program, allowing the agency to require drug makers to reclassify their drugs and impose civil monetary penalties when drugs are knowingly misclassified.

Advertise with us

Currently, drug companies are responsible for ensuring that their products are correctly classified.

For years, Mylan’s EpiPen emergency allergy shot was classified as a generic instead of a brand name drug.

“The Centers for Medicare & Medicaid services was made aware of the misclassification for years but did nothing,” according to a summary of the bill released by the senators. “Overall, the legislation will prevent the EpiPen fiasco from happening again.”

The bill would create oversight mechanisms, such as a requirement that Health and Human Services provides reports to Congress about how its new authority has been used and the actions taken to reclassify drugs.

“While families struggle to afford medicines like EpiPen, drug makers are busy manipulating the system to squeeze taxpayers even more,” Mr. Wyden said in a statement. “This bipartisan bill will crack down on Big Pharma’s games and help prevent them from taking advantage of Medicaid, a program meant to protect the most vulnerable.”

Advertise with us

Mr. Wyden said he was hopeful that the bill would pass by the end of the year.

Mylan’s classification issue was raised with the Justice Department in 2014 by French drugmaker Sanofi, which at the time was paying higher rebates on its Auvi-Q epinephrine auto-injector.

Mylan, which is run from executive offices in Cecil, settled with the department without admitting wrongdoing.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.